Skip to main content

Advertisement

SpringerLink
Log in

Whole-body kinetics and dosimetry ofl-3-[123I]iodo-α-methyltyrosine

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The synthetic amino acidl-3-[123I]iodo-α-methyltyrosine (IMT) is currently under clinical evaluation as a single-photon emission tomography (SPET) tracer of amino acid uptake in brain tumours. So far, dosimetric data in respect of IMT are not available. Therefore we investigated the whole-body distribution of IMT in six patients with cerebral gliomas and the radiation doses were estimated. Whole-body scans were acquired at 1.5, 3 and 5 h after i.v. injection of 370–550 MBq IMT. The bladder was voided prior to each scan and the radioactivity excreted in the urine was measured. Based on the MIRD-11 method and the updated MIRDOSE3, the mean absorbed doses for various organs and the effective dose were calculated from geometric means of the anterior and posterior whole-body scans using seven source organs and the residence time. IMT was predominantly excreted by the kidneys (52.8%±11.5% at 1.5 h p.i., 63.0%±15.7% at 3 h p.i. and 74.6%±9.8% at 5 h p.i.). No organ system other than the urinary tract showed significant retention of the tracer. Early whole-body scans revealed slightly increased tracer uptake in the liver and in the bowel. Highest absorbed doses were found for the urinary bladder wall (0.047 mGy/MBq), the kidneys (0.010 mGy/MBq), the lower large intestinal wall (0.011 mGy/MBq) and the upper large intestinal wall (0.008 mGy/MBq). The effective dose according to ICRP 60 was estimated to be 0.0073 mSv/MBq for adults. This leads to an effective dose of 3.65 mSv in a typical brain SPET study using 500 MBq IMT. The MIRDOSE3 scheme yielded similar results. Thus, in spite of the relatively high tracer dose required for optimal brain scanning, radiation exposure in SPET studies with IMT is in the normal range of routine nuclear medicine investigations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A. [11C]-l-methionine uptake in gliomas.Neurosurgery 1989; 25: 720–728.

    PubMed  Google Scholar 

  2. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T, Uemura K, Yasui N Mineura K. Cerebral glioma: evaluation with methionine PET.Radiology 1993; 186: 45–53.

    PubMed  Google Scholar 

  3. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M, Eriksson L, Johnstrom P. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference.Acta Radiol 1989; 30: 225–232.

    PubMed  Google Scholar 

  4. Biersack HJ, Coenen HH, Stöcklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O. Imaging of brain tumors withl-3-[123I]Iodo-α-methyl tyrosine and SPECT.J Nucl Med 1989; 30: 110–112.

    PubMed  Google Scholar 

  5. Langen KJ, Coenen HH, Roosen N, Kling P, Muzik O, Herzog H, Kuwert T, Stöcklin G, Feinendegen LE. SPECT studies of brain tumors withl-3-[123I]Iodo-α-methyl tyrosine: comparison with PET,124IMT and first clinical results.J Nucl Med 1990; 31: 281–286.

    PubMed  Google Scholar 

  6. Langen KJ, Roosen N, Coenen HH, Kuikka JT, Kuwert T, Herzog H, Stöcklin G, Feinendegen LE. Brain and brain tumor uptake ofl-3-[123I]Iodo-α-methyl tyrosine: competition with naturall-amino acids.J Nucl Med 1991; 32:1225–1228.

    PubMed  Google Scholar 

  7. Kawai K, Fujibayashi Y, Saji H, Yonekura Y, Konishi J, Kubodera A, Yokoyama A. A strategy for the study of cerebral amino acid transport using iodine-123-labelled amino acid radiopharmaceutical: 3-iodo-alpha-methyl-l-tyrosine.J Nucl Med 1991; 32: 819–824.

    PubMed  Google Scholar 

  8. Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G, Heiss WD. Increased amino acid transport into brain tumors measured by PET ofl-[2-18F]fluorotyrosine.J Nucl Med 1991; 32: 1338–1346.

    PubMed  Google Scholar 

  9. Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW. [123I]-Iodo-α-methyl-tyrosine SPELT and [methyl-11C]-l-me-thionine uptake in cerebral gliomas: a comparative study using SPECT and PET.J Nucl Med 1997; 38: 517–522.

    PubMed  Google Scholar 

  10. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, Samnick S, Maasjosthusmann U, Lerch H, Gildehaus FJ, Wassmann H, Schober O. Uptake of iodine-123-α-methyl tyrosine by gliomas and non-neoplastic brain lesions.Eur J Nucl Med 1996; 23: 1345–1353.

    PubMed  Google Scholar 

  11. Guth-Tougelidis B, Müller S, Mehdom MM, Knust EJ, Dutschka K, Reiners C. Anreicherung vondl-3-123I-α-methyltyrosin in Hirntumorrezidiven.Nucl-Med 1995: 34: 71–75.

    Google Scholar 

  12. Schmidt D, Wunderlich G, Langen KJ, Ziemons K, Kiwit JCW, Holschbach M, Müller-Gärtner HW I-123-α-methyl-tyrosine (IMT) SPELT for evaluation of chemotherapy in cerebral gliomas.J Nucl Med 1996; 37: 354P.

  13. Tisljar U, Kloster G, Ritzl F, Stöcklin G. Accumulation of radioiodinatedl-α-methyltyrosine in pancreas of mice: concise communication.J Nucl Med 1979: 20: 973–976.

    PubMed  Google Scholar 

  14. Kloster G, Bockslaff H.l-3-123I-α-methyltyrosine for melanoma detection: a comparative evaluation.Int J Nucl Med Biol 1982; 9: 259–269.

    PubMed  Google Scholar 

  15. Krummeich C, Holschbach M, Stöcklin G. Direct electrophilic radioiodinadon of tyrosine analogues: their in-vivo stability and brain uptake in mice.Appl Radiat Isot 1994; 45: 929–935.

    PubMed  Google Scholar 

  16. Budinger TF. Quantitative nuclear medicine imaging: application of computers to the gamma camera and whole-body scanner. In:Recent Advances in Nuclear Medicine 1974: 41–130.

  17. Sorensen JA. Quantitative measurement of radioactivity in vivo by whole-body counting. In: Hine GJ, et al., eds.Instrumentation in nuclear medicine, vol 2. New York: Academic Press; 1974: 311–347.

    Google Scholar 

  18. Loevinger R, Budinger TF, Watson EE.MIRD — primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1988.

    Google Scholar 

  19. Snyder WS, Ford MR, Warner GG, Watson SB. “S,” absorbed dose per unit cumulated activity for selected radionuclides and organs.MIRD Pamphlet No. 11. New York, The Society of Nuclear Medicine, 1975.

    Google Scholar 

  20. Recommendations of the International Commission on Radiological Protection.ICRP publication 60. New York: Pergamon Press, 1991.

  21. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine.J Nucl Med 1996; 37:538–546.

    PubMed  Google Scholar 

  22. Deehan B, Carnochan P, Trivedi M, Tombs A. Uptake and distribution ofl-3-[125I]iodo-α-methyl tyrosine in experimental rat tumours: comparison with blood flow and growth rate.Eur J Nucl Med 1993; 20:101–106.

    PubMed  Google Scholar 

  23. Dey HM, Seibyl JP, Stubbs JB, Zoghbi SS, Baldwin RM, Smith EO, Zubal IG, Zea-Ponce Y, Olson C, Charney DS, Hoffer PB, Innis RB. Human biodistribution and dosimetry of the SPECT benzodiazepie receptor radioligand iodine-123-iomazenil.J Nucl Med 1994; 35: 399–404.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medicine, Research Center Jülich, D-52426, Jülich, Germany

    Daniela Schmidt, Karl-Josef Langen, Hans Herzog, Jochen Wirths, Karl Ziemons & Hans -W. Müller-Gärtner

  2. Institute of Nuclear Chemistry, Research Center Jülich, Jülich, Germany

    Markus Holschbach & Heinz H. Coenen

  3. Department of Neurosurgery, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany

    Jürgen C. W. Kiwit

Authors
  1. Daniela Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karl-Josef Langen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Herzog
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jochen Wirths
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Holschbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jürgen C. W. Kiwit
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Karl Ziemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Heinz H. Coenen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hans -W. Müller-Gärtner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, D., Langen, KJ., Herzog, H. et al. Whole-body kinetics and dosimetry ofl-3-[123I]iodo-α-methyltyrosine. Eur J Nucl Med 24, 1162–1166 (1997). https://doi.org/10.1007/BF01254250

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01254250

Key words

Search

Navigation